CYTO-200 Noroxymorphone Platform
CYTO-200 program therapies, are noroxymorphone analogs developed by discovering the anti-angiogenic and anti-inflammatory properties of naltrexone, yielding a new way of fighting cancer, inflammatory, autoimmune and infectious diseases.
After years of work with naltrexone and met-enkepahlin, and discovering their anti-angiogenic and anti-inflammatory properties, Cytocom developed a proprietary drug discovery and development platform known as AIMS™: Advanced Immunomodulating Multi-receptor System. Through AIMS™, we are expanding our understanding of the relationship between noroxymorphone and proenkephalin analogs to determine how multiple factors impact pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. Through methodical property analysis we have discovered, with more accuracy, targets with the improved properties to address specific patient needs eliciting immune response levels not achieved by other published immunotherapy approaches.
CYTO-400 Proenkephalin Platform
CYTO-400 program therapies are proenkephalin analogs developed to target multiple receptors associated with cancer, inflammatory, autoimmune, and infectious diseases
After years of work with naltrexone and met-enkepahlin, and discovering their anti-angiogenic and anti-inflammatory properties, Cytocom developed a proprietary drug discovery and development platform known as AIMS™: Advanced Immunomodulating Multi-receptor System. Through AIMS™, we are expanding our understanding of the relationship between noroxymorphone and proenkephalin analogs to determine how multiple factors impact pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. Through methodical property analysis we have discovered, with more accuracy, targets with the improved properties to address specific patient needs eliciting immune response levels not achieved by other published immunotherapy approaches.
CYTO-600 TLR5 Platform
CYTO-600 TLR5 program therapies are analogs developed to target multiple indications such as: hematology, acute radiation syndrome, cancer, inflammatory, autoimmune, and infectious diseases with a focus on TLR5. CYTO-600 TLR5 is a recombinant protein that acts as an agonist of toll-like receptor 5 (TLR5), an innate immunity receptor. CYTO-600 activation of TLR5 triggers NF-kB signaling, mobilizing an innate immune response that drives expression of numerous genes, including inhibitors of apoptosis, scavengers of reactive oxygen species, and a spectrum of protective or regenerative cytokines.
Up Coming Events
Event: Conference call and live audio webcast
Date: Monday, August 16, 2021
Time: 8:30 a.m. ET
This event has ended. An archive is available here
Registration: https://www.webcaster4.com/Webcast/Page/2462/42483
Telephone Access (US): 888-317-6003
Telephone Access (International): 412-317-6061
Access Code for All Callers: 3735775
Past Events
Event: Investor Call
Date: July 7, 2021
Registration: https://www.webcaster4.com/Webcast/Page/2462/41942
Presentation: Available Here.